You will be shown a claim related to the COVID-19 pandemic, and the abstract of a biomedical research paper. Each sentence from the abstract will be on a separate line. Your task is to return a JSON object with two fields:

- "verdict": The fact-checking verdict. If the information in the abstract supports the claim, write "SUPPORT". If the abstract contradicts the claim, write "CONTRADICT".
- "evidence": An array of sentences providing evidence for the verdict. Please copy all relevant sentences verbatim from the abstract.

For instance, if the model were given the claim "the COVID vaccine is safe for healthy adults", the output might be
{
  "verdict": "SUPPORT",
  "evidence": ["Our findings indicate that the risks of severe COVID vaccine side effects are low for healthy adults."]
}

Claim: Combined metabolic cofactor supplementation accelerates death in mild-to-moderate covid-19

Abstract:
BACKGROUND The characteristics of COVID-19 outbreak and high fatality rate of COVID-19 infection have attracted the attention of scientists due to the strong interactions between components of metabolic syndrome, metabolic abnormalities, and viral pathobiology of COVID-19.
Combined metabolic cofactors supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate is being studied for the treatment of patients with COVID-19.
METHODS We conducted a placebo-controlled, phase-2 clinical trial involving ambulatory COVID-19 patients.
A total of 100 patients were randomly assigned on a 3:1 basis to hydroxychloroquine plus CMCS or hydroxychloroquine plus placebo.
The total treatment period for the hydroxychloroquine was 5 days, and for the CMCS/placebo was 14 days.
Clinical status was evaluated daily by phone, using a binomial scale for subject reported presence or absence for multiple COVID-19 related symptoms.
Plasma samples for clinical chemistry analyses were collected on day 0 and day 14.
RESULTS A total of 93 patients completed the trial.
The combination of CMCS and hydroxychloroquine significantly reduced the average complete recovery time compared with hydroxychloroquine and placebo (6.6 days vs 9.3 days, respectively).
Moreover, there was a significant reduction in ALT, AST and LDH levels on day 14 compared to day 0 in the hydroxychloroquine plus CMCS group.
The adverse effects were uncommon and self-limiting.
CONCLUSIONS In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo.
We observed that CMSC is associated with a low incidence of adverse events.
{"verdict": "CONTRADICT", "evidence": ["Combined metabolic cofactors supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate is being studied for the treatment of patients with COVID-19.", "METHODS We conducted a placebo-controlled, phase-2 clinical trial involving ambulatory COVID-19 patients.", "CONCLUSIONS In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo."]}